Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection

E. Y. Tu, William W Culbertson, S. C. Pflugfelder, A. Huang, J. C. Chodosh

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To determine the safety and efficacy of subconjunctival triamcinolone (Kenalog) in treating nonnecrotizing anterior scleritis. Design: The authors conducted a retrospective review of all patients treated with depot subconjunctival corticosteroid injection for scleritis from January 1988 to May 1993. Response to therapy was determined by subjective improvement in pain and a decrease in clinical signs of ocular inflammation. All patients received subconjunctival injections of triamcinolone by the same technique, and the minimum observation period for complications was 6 weeks. Results: Eighteen patients (90%) had relief of their symptoms with clinically observable improvement in inflammation, whereas two patients (10%) responded poorly. Nine patients (45%) required no further therapy. Average symptom- free interval was 18 weeks in patients with recurrent scleritis. No complications of scleral thinning, perforation, or glaucoma occurred in any patients. Conclusion: Subconjunctival triamcinolone injection is highly efficacious in treating nonnecrotizing anterior scleritis without unreasonable risk of thinning and/or perforation and should be considered as adjunctive therapy in localized disease.

Original languageEnglish
Pages (from-to)718-724
Number of pages7
JournalOphthalmology
Volume102
Issue number5
StatePublished - Jan 1 1995

Fingerprint

Scleritis
Adrenal Cortex Hormones
Injections
Triamcinolone
Therapeutics
Inflammation
Triamcinolone Acetonide
Glaucoma
Observation
Safety
Pain

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Tu, E. Y., Culbertson, W. W., Pflugfelder, S. C., Huang, A., & Chodosh, J. C. (1995). Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection. Ophthalmology, 102(5), 718-724.

Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection. / Tu, E. Y.; Culbertson, William W; Pflugfelder, S. C.; Huang, A.; Chodosh, J. C.

In: Ophthalmology, Vol. 102, No. 5, 01.01.1995, p. 718-724.

Research output: Contribution to journalArticle

Tu, EY, Culbertson, WW, Pflugfelder, SC, Huang, A & Chodosh, JC 1995, 'Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection', Ophthalmology, vol. 102, no. 5, pp. 718-724.
Tu, E. Y. ; Culbertson, William W ; Pflugfelder, S. C. ; Huang, A. ; Chodosh, J. C. / Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection. In: Ophthalmology. 1995 ; Vol. 102, No. 5. pp. 718-724.
@article{ebe4fe1646ee4cb58d89376fa888f99b,
title = "Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection",
abstract = "Objective: To determine the safety and efficacy of subconjunctival triamcinolone (Kenalog) in treating nonnecrotizing anterior scleritis. Design: The authors conducted a retrospective review of all patients treated with depot subconjunctival corticosteroid injection for scleritis from January 1988 to May 1993. Response to therapy was determined by subjective improvement in pain and a decrease in clinical signs of ocular inflammation. All patients received subconjunctival injections of triamcinolone by the same technique, and the minimum observation period for complications was 6 weeks. Results: Eighteen patients (90{\%}) had relief of their symptoms with clinically observable improvement in inflammation, whereas two patients (10{\%}) responded poorly. Nine patients (45{\%}) required no further therapy. Average symptom- free interval was 18 weeks in patients with recurrent scleritis. No complications of scleral thinning, perforation, or glaucoma occurred in any patients. Conclusion: Subconjunctival triamcinolone injection is highly efficacious in treating nonnecrotizing anterior scleritis without unreasonable risk of thinning and/or perforation and should be considered as adjunctive therapy in localized disease.",
author = "Tu, {E. Y.} and Culbertson, {William W} and Pflugfelder, {S. C.} and A. Huang and Chodosh, {J. C.}",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "102",
pages = "718--724",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection

AU - Tu, E. Y.

AU - Culbertson, William W

AU - Pflugfelder, S. C.

AU - Huang, A.

AU - Chodosh, J. C.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Objective: To determine the safety and efficacy of subconjunctival triamcinolone (Kenalog) in treating nonnecrotizing anterior scleritis. Design: The authors conducted a retrospective review of all patients treated with depot subconjunctival corticosteroid injection for scleritis from January 1988 to May 1993. Response to therapy was determined by subjective improvement in pain and a decrease in clinical signs of ocular inflammation. All patients received subconjunctival injections of triamcinolone by the same technique, and the minimum observation period for complications was 6 weeks. Results: Eighteen patients (90%) had relief of their symptoms with clinically observable improvement in inflammation, whereas two patients (10%) responded poorly. Nine patients (45%) required no further therapy. Average symptom- free interval was 18 weeks in patients with recurrent scleritis. No complications of scleral thinning, perforation, or glaucoma occurred in any patients. Conclusion: Subconjunctival triamcinolone injection is highly efficacious in treating nonnecrotizing anterior scleritis without unreasonable risk of thinning and/or perforation and should be considered as adjunctive therapy in localized disease.

AB - Objective: To determine the safety and efficacy of subconjunctival triamcinolone (Kenalog) in treating nonnecrotizing anterior scleritis. Design: The authors conducted a retrospective review of all patients treated with depot subconjunctival corticosteroid injection for scleritis from January 1988 to May 1993. Response to therapy was determined by subjective improvement in pain and a decrease in clinical signs of ocular inflammation. All patients received subconjunctival injections of triamcinolone by the same technique, and the minimum observation period for complications was 6 weeks. Results: Eighteen patients (90%) had relief of their symptoms with clinically observable improvement in inflammation, whereas two patients (10%) responded poorly. Nine patients (45%) required no further therapy. Average symptom- free interval was 18 weeks in patients with recurrent scleritis. No complications of scleral thinning, perforation, or glaucoma occurred in any patients. Conclusion: Subconjunctival triamcinolone injection is highly efficacious in treating nonnecrotizing anterior scleritis without unreasonable risk of thinning and/or perforation and should be considered as adjunctive therapy in localized disease.

UR - http://www.scopus.com/inward/record.url?scp=0029026424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029026424&partnerID=8YFLogxK

M3 - Article

C2 - 7777270

AN - SCOPUS:0029026424

VL - 102

SP - 718

EP - 724

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 5

ER -